EVAL OF ANTI-INFLAMMATORY EFFECTS OF AZITHROMYCIN IN PTS W/CF

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。患有囊性纤维化(CF)的儿童有患与慢性炎症和下呼吸道感染相关的终末期肺部疾病的风险。尽管在过去20年中长期存活的趋势令人鼓舞，但肺部疾病仍然是CF患者发病率和死亡率的最常见原因。虽然抗炎治疗通常被认为对患者有益，但目前还没有单一的药物在这一患者群体中广泛使用，主要是因为对先前研究的药物，如口服类固醇和布洛芬的长期安全性的担忧。最近完成的一项关于阿奇霉素在CF患者中使用的研究结果令人振奋，促使囊性纤维化基金会向CF护理人员发布新闻稿，建议考虑在选定的患者中使用阿奇霉素。这项临床研究项目旨在确定阿奇霉素在我们佛罗里达大学诊所接受这种治疗的儿童的抗炎效果。有待检验的假设是，在接受阿奇霉素治疗的患者中，痰中炎症标志物的下降伴随着临床益处。结果将确定这种治疗的效用，因为它与所谓的作用机制有关。这些发现不仅将提供与直接患者护理相关的临床信息，而且还将补充我们正在进行的关于患有CF相关肺部疾病的儿童肺部疾病发病机制的研究工作。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Children with the cystic fibrosis (CF) are at risk for end stage lung disease associated with chronic inflammation and infection of the lower respiratory tract. Despite encouraging trends in long term survival over the past 20 years, pulmonary disease remains the most common cause of morbidity and mortality in patients with CF. Although anti-inflammatory therapy is generally thought to be of benefit to patients, there is no single agent currently in wide-spread use in this patient population, primarily due to concerns regarding the long-term safety of previously studied agents such as oral steroids and ibuprofen. The results of a recently completed study on the use of azithromycin in patients with CF were promising enough to prompt the Cystic Fibrosis Foundation to issue a news release to CF caregivers recommending consideration of its use in selected patients. This clinical research project is designed to characterize the anti-inflammatory effect of azithromycin in children placed on this treatment in our clinic at the University of Florida. The hypothesis to be tested is that a decline in sputum inflammatory markers accompanies clinical benefit in patients treated with azithromycin. Results will define the utility of this treatment as it relates to the purported mechanism of action. Findings will not only provide clinical information relevant to direct patient care, but will also complement our ongoing research efforts regarding the pathogenesis of lung disease in children with CF-related lung disease.